APO RESEARCH · REPORT
VRE and MRSA Antibiotic
Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) are specific, antibiotic-resistant bacteria that spread by contact and can cause serious infections. MRSA can be spread by touching articles that have been contaminated by the skin of an infected or colonized person, such as towels, sheets, and wound dressings; VRE can be transmitted by touching articles soiled by an infected person’s feces. Both of these bacteria survive well on hands and for weeks on inanimate objects. Colonization occurs when bacteria are present on or in the body (i.e., nose, skin, rectum, moist areas of the body and the newborn’s umbilicus) without causing illness.
Product & engineering
Understand the product.
Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) are specific, antibiotic-resistant bacteria that spread by contact and can cause serious infections. MRSA can be spread by touching articles that have been contaminated by the skin of an infected or colonized person, such as towels, sheets, and wound dressings; VRE can be transmitted by touching articles soiled by an infected person’s feces. Both of these bacteria survive well on hands and for weeks on inanimate objects. Colonization occurs when bacteria are present on or in the body (i.e., nose, skin, rectum, moist areas of the body and the newborn’s umbilicus) without causing illness.
An antibiotic is a type of antimicrobial substance active against bacteria. It is the most important type of antibacterial agent for fighting bacterial infections, and antibiotic medications are widely used in the treatment and prevention of such infections. They may either kill or inhibit the growth of bacteria.
Selected research
Industry Research
VRE and MRSA Antibiotic Industry Research Report 2026
Market perspective
Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) are specific, antibiotic-resistant bacteria that spread by contact and can cause serious infections. MRSA can be spread by touching articles that have been contaminated by the skin of an infected or colonized person, such as towels, sheets, and wound dressings; VRE can be transmitted by touching articles soiled by an infected person’s feces. Both of these bacteria survive well on hands and for weeks on inanimate objects. Colonization occurs when bacteria are present on or in the body (i.e., nose, skin, rectum, moist areas of the body and the newborn’s umbilicus) without causing illness.
An antibiotic is a type of antimicrobial substance active against bacteria. It is the most important type of antibacterial agent for fighting bacterial infections, and antibiotic medications are widely used in the treatment and prevention of such infections. They may either kill or inhibit the growth of bacteria.
The market for is VRE and MRSA antibiotic market fragmented with players such as Pfizer, Lilly, Sanofi Aventis, Merck, Fresenius Kabi, Xellia Pharmaceuticals (Novo Holdings), Zhejiang Medicine, Zhejiang Hisun Pharmaceutical, North China Pharmaceutical. Among the companies, pfizer contributed 17% of the market, which is the biggest in 2020.In terms of product, linezolid is the largest segment, with a share over 38%. And in terms of application, the largest application is hospitals.
Read the full market overview
Report Scope
This report quantifies the global VRE and MRSA Antibiotic market in terms of revenue (US$ million) and, where applicable, sales volume (M Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
VRE and MRSA Antibiotic Market by Company
Pfizer
Lilly
Sanofi Aventis
Merck
Fresenius Kabi
Xellia Pharmaceuticals (Novo Holdings)
Zhejiang Medicine
Zhejiang Hisun Pharmaceutical
North China Pharmaceutical
Korea United Pharm
VRE and MRSA Antibiotic Segment by Type
Vancomycin
Teicoplanin
Linezolid
Daptomycin
Others
VRE and MRSA Antibiotic Segment by Application
Hospitals
Clinics
Others
VRE and MRSA Antibiotic Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VRE and MRSA Antibiotic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of VRE and MRSA Antibiotic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VRE and MRSA Antibiotic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of VRE and MRSA Antibiotic manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of VRE and MRSA Antibiotic by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of VRE and MRSA Antibiotic in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Vancomycin
- Teicoplanin
- Linezolid
- Daptomycin
- Others
Applications
- Hospitals
- Clinics
- Others
Companies covered
- Pfizer
- Lilly
- Sanofi Aventis
- Merck
- Fresenius Kabi
- Xellia Pharmaceuticals (Novo Holdings)
- Zhejiang Medicine
- Zhejiang Hisun Pharmaceutical
- North China Pharmaceutical
- Korea United Pharm
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global VRE and MRSA Antibiotic Market Size (2021-2032)
- 2.2.2 Global VRE and MRSA Antibiotic Sales (2021-2032)
- 2.2.3 Global VRE and MRSA Antibiotic Market Average Price (2021-2032)
- 2.3 VRE and MRSA Antibiotic by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Vancomycin
- 2.3.3 Teicoplanin
- 2.3.4 Linezolid
- 2.3.5 Daptomycin
- 2.3.6 Others
- 2.4 VRE and MRSA Antibiotic by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Clinics
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global VRE and MRSA Antibiotic Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global VRE and MRSA Antibiotic Sales (M Units) of Manufacturers (2021-2026)
- 3.3 Global VRE and MRSA Antibiotic Revenue of Manufacturers (2021-2026)
- 3.4 Global VRE and MRSA Antibiotic Average Price by Manufacturers (2021-2026)
- 3.5 Global VRE and MRSA Antibiotic Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of VRE and MRSA Antibiotic, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of VRE and MRSA Antibiotic, Product Type & Application
- 3.8 Global Manufacturers of VRE and MRSA Antibiotic, Established Date
- 3.9 Global VRE and MRSA Antibiotic Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Pfizer
- 4.1.1 Pfizer Company Information
- 4.1.2 Pfizer Business Overview
- 4.1.3 Pfizer VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Pfizer VRE and MRSA Antibiotic Product Portfolio
- 4.1.5 Pfizer Recent Developments
- 4.2 Lilly
- 4.2.1 Lilly Company Information
- 4.2.2 Lilly Business Overview
- 4.2.3 Lilly VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Lilly VRE and MRSA Antibiotic Product Portfolio
- 4.2.5 Lilly Recent Developments
- 4.3 Sanofi Aventis
- 4.3.1 Sanofi Aventis Company Information
- 4.3.2 Sanofi Aventis Business Overview
- 4.3.3 Sanofi Aventis VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sanofi Aventis VRE and MRSA Antibiotic Product Portfolio
- 4.3.5 Sanofi Aventis Recent Developments
- 4.4 Merck
- 4.4.1 Merck Company Information
- 4.4.2 Merck Business Overview
- 4.4.3 Merck VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck VRE and MRSA Antibiotic Product Portfolio
- 4.4.5 Merck Recent Developments
- 4.5 Fresenius Kabi
- 4.5.1 Fresenius Kabi Company Information
- 4.5.2 Fresenius Kabi Business Overview
- 4.5.3 Fresenius Kabi VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Fresenius Kabi VRE and MRSA Antibiotic Product Portfolio
- 4.5.5 Fresenius Kabi Recent Developments
- 4.6 Xellia Pharmaceuticals (Novo Holdings)
- 4.6.1 Xellia Pharmaceuticals (Novo Holdings) Company Information
- 4.6.2 Xellia Pharmaceuticals (Novo Holdings) Business Overview
- 4.6.3 Xellia Pharmaceuticals (Novo Holdings) VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Xellia Pharmaceuticals (Novo Holdings) VRE and MRSA Antibiotic Product Portfolio
- 4.6.5 Xellia Pharmaceuticals (Novo Holdings) Recent Developments
- 4.7 Zhejiang Medicine
- 4.7.1 Zhejiang Medicine Company Information
- 4.7.2 Zhejiang Medicine Business Overview
- 4.7.3 Zhejiang Medicine VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Zhejiang Medicine VRE and MRSA Antibiotic Product Portfolio
- 4.7.5 Zhejiang Medicine Recent Developments
- 4.8 Zhejiang Hisun Pharmaceutical
- 4.8.1 Zhejiang Hisun Pharmaceutical Company Information
- 4.8.2 Zhejiang Hisun Pharmaceutical Business Overview
- 4.8.3 Zhejiang Hisun Pharmaceutical VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Zhejiang Hisun Pharmaceutical VRE and MRSA Antibiotic Product Portfolio
- 4.8.5 Zhejiang Hisun Pharmaceutical Recent Developments
- 4.9 North China Pharmaceutical
- 4.9.1 North China Pharmaceutical Company Information
- 4.9.2 North China Pharmaceutical Business Overview
- 4.9.3 North China Pharmaceutical VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 North China Pharmaceutical VRE and MRSA Antibiotic Product Portfolio
- 4.9.5 North China Pharmaceutical Recent Developments
- 4.10 Korea United Pharm
- 4.10.1 Korea United Pharm Company Information
- 4.10.2 Korea United Pharm Business Overview
- 4.10.3 Korea United Pharm VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Korea United Pharm VRE and MRSA Antibiotic Product Portfolio
- 4.10.5 Korea United Pharm Recent Developments
5 Global VRE and MRSA Antibiotic Market Scenario by Region
- 5.1 Global VRE and MRSA Antibiotic Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global VRE and MRSA Antibiotic Sales by Region: 2021-2032
- 5.2.1 Global VRE and MRSA Antibiotic Sales by Region: 2021-2026
- 5.2.2 Global VRE and MRSA Antibiotic Sales by Region: 2027-2032
- 5.3 Global VRE and MRSA Antibiotic Revenue by Region: 2021-2032
- 5.3.1 Global VRE and MRSA Antibiotic Revenue by Region: 2021-2026
- 5.3.2 Global VRE and MRSA Antibiotic Revenue by Region: 2027-2032
- 5.4 North America VRE and MRSA Antibiotic Market Facts & Figures by Country
- 5.4.1 North America VRE and MRSA Antibiotic Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America VRE and MRSA Antibiotic Sales by Country (2021-2032)
- 5.4.3 North America VRE and MRSA Antibiotic Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe VRE and MRSA Antibiotic Market Facts & Figures by Country
- 5.5.1 Europe VRE and MRSA Antibiotic Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe VRE and MRSA Antibiotic Sales by Country (2021-2032)
- 5.5.3 Europe VRE and MRSA Antibiotic Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific VRE and MRSA Antibiotic Market Facts & Figures by Country
- 5.6.1 Asia Pacific VRE and MRSA Antibiotic Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific VRE and MRSA Antibiotic Sales by Country (2021-2032)
- 5.6.3 Asia Pacific VRE and MRSA Antibiotic Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America VRE and MRSA Antibiotic Market Facts & Figures by Country
- 5.7.1 South America VRE and MRSA Antibiotic Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America VRE and MRSA Antibiotic Sales by Country (2021-2032)
- 5.7.3 South America VRE and MRSA Antibiotic Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa VRE and MRSA Antibiotic Market Facts & Figures by Country
- 5.8.1 Middle East and Africa VRE and MRSA Antibiotic Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa VRE and MRSA Antibiotic Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa VRE and MRSA Antibiotic Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global VRE and MRSA Antibiotic Sales by Type (2021-2032)
- 6.1.1 Global VRE and MRSA Antibiotic Sales by Type (2021-2032) & (M Units)
- 6.1.2 Global VRE and MRSA Antibiotic Sales Market Share by Type (2021-2032)
- 6.2 Global VRE and MRSA Antibiotic Revenue by Type (2021-2032)
- 6.2.1 Global VRE and MRSA Antibiotic Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global VRE and MRSA Antibiotic Revenue Market Share by Type (2021-2032)
- 6.3 Global VRE and MRSA Antibiotic Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global VRE and MRSA Antibiotic Sales by Application (2021-2032)
- 7.1.1 Global VRE and MRSA Antibiotic Sales by Application (2021-2032) & (M Units)
- 7.1.2 Global VRE and MRSA Antibiotic Sales Market Share by Application (2021-2032)
- 7.2 Global VRE and MRSA Antibiotic Revenue by Application (2021-2032)
- 7.2.1 Global VRE and MRSA Antibiotic Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global VRE and MRSA Antibiotic Revenue Market Share by Application (2021-2032)
- 7.3 Global VRE and MRSA Antibiotic Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 VRE and MRSA Antibiotic Value Chain Analysis
- 8.1.1 VRE and MRSA Antibiotic Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 VRE and MRSA Antibiotic Production Mode & Process
- 8.2 VRE and MRSA Antibiotic Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 VRE and MRSA Antibiotic Distributors
- 8.2.3 VRE and MRSA Antibiotic Customers
9 Global VRE and MRSA Antibiotic Analyzing Market Dynamics
- 9.1 VRE and MRSA Antibiotic Industry Trends
- 9.2 VRE and MRSA Antibiotic Industry Drivers
- 9.3 VRE and MRSA Antibiotic Industry Opportunities and Challenges
- 9.4 VRE and MRSA Antibiotic Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst